[Amatoxin-containing mushroom poisoning: An update].

Autor: Caré W; Centre antipoison de Paris, fédération de toxicologie (FeTox), hôpital Fernand-Widal, AP-HP, 200, rue du Faubourg-Saint-Denis, 75010 Paris, France; Service de médecine interne, hôpital d'instruction des armées Bégin, 69, avenue de Paris, 91460 Saint-Mandé, France; Université Paris-Cité, Inserm UMR-S 1144, optimisation thérapeutique en neuropsychopharmacologie, 4, avenue de l'Observatoire, 75006 Paris, France. Electronic address: weniko.care@aphp.fr., Bruneau C; Centre antipoison d'Angers, centre hospitalier universitaire d'Angers, 4, rue Larrey, 49000 Angers, France., Rapior S; CEFE, CNRS, université de Montpellier, EPHE, IRD, laboratoire de botanique, phytochimie et mycologie, UFR des sciences pharmaceutiques et biologiques, 15, avenue Charles-Flahault, CS 14491, 34093 Montpellier cedex 5, France., Langrand J; Centre antipoison de Paris, fédération de toxicologie (FeTox), hôpital Fernand-Widal, AP-HP, 200, rue du Faubourg-Saint-Denis, 75010 Paris, France; Université Paris-Cité, Inserm UMR-S 1144, optimisation thérapeutique en neuropsychopharmacologie, 4, avenue de l'Observatoire, 75006 Paris, France., Le Roux G; Centre antipoison d'Angers, centre hospitalier universitaire d'Angers, 4, rue Larrey, 49000 Angers, France; Institut de recherche en santé, environnement et travail (IRSET), Inserm UMR 1085, équipe 10 ESTER, université d'Angers, 49000 Angers, France., Vodovar D; Centre antipoison de Paris, fédération de toxicologie (FeTox), hôpital Fernand-Widal, AP-HP, 200, rue du Faubourg-Saint-Denis, 75010 Paris, France; Université Paris-Cité, Inserm UMR-S 1144, optimisation thérapeutique en neuropsychopharmacologie, 4, avenue de l'Observatoire, 75006 Paris, France; UFR de médecine, université de Paris, 75006 Paris, France.
Jazyk: francouzština
Zdroj: La Revue de medecine interne [Rev Med Interne] 2024 Jul; Vol. 45 (7), pp. 423-430. Date of Electronic Publication: 2023 Nov 08.
DOI: 10.1016/j.revmed.2023.10.459
Abstrakt: Amatoxin-containing mushroom poisoning occurs after consumption of certain mushroom species, of the genera Amanita, Lepiota and Galerina. Amanita phalloides is the most implicated species, responsible for over more than 90% of mushroom-related deaths. The α-amanitin is responsible for most of the observed effects. Symptoms are characterized by severe delayed gastrointestinal disorders (more than six hours after ingestion). The liver being the main target organ, outcome is marked by an often severe hepatitis which can evolve towards terminal liver failure, justifying orthotopic liver transplantation. Acute renal failure is common. Diagnosis of amatoxin-containing mushroom poisoning is based primarily on clinical data; it can be biologically confirmed using detection of amatoxins, especially from urine samples. In the absence of an antidote, early hospital management is essential. It is based on supportive care (early compensation of hydroelectrolytic losses), gastrointestinal digestive decontamination, elimination enhancement, amatoxin uptake inhibitors and antioxidant therapy. Combined therapy associating silibinin and N-acetylcysteine is recommended. Prognosis of this severe poisoning has greatly benefited from improved resuscitation techniques. Mortality is currently less than 10%. In the event of a suspected or confirmed case, referral to a Poison Control Center is warranted in order to establish the diagnosis and guide the medical management of patients in an early and appropriate way.
(Copyright © 2023 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: